Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Notifies Nanogen of Delisting Status on Minimum Bid Price

NEW YORK (GenomeWeb News) – The Nasdaq Stock Market has notified Nanogen that it may delist the company’s stock from the market due to failure to maintain a minimum bid price for 30 days, the company said Friday.
 
The notification has no effect on Nanogen’s stock currently, but if Nanogen’s shares do not trade at or above $1 per share for a period of 10 consecutive days in the next six months the firm will receive written notification from Nasdaq that its shares will be delisted.
 
The company’s stock has been trading under $1 steadily since mid-September and closed Friday at $.63 a share.
 
If Nanogen is delisted in May it may transfer to the Nasdaq Capital Market, at which time it will receive another 180 days to comply with the minimum bid rule.
 
Nanogen recently announced that it would shutter its microarray business, lay off around 20 percent of its staff, and realign the company behind its real-time PCR and point-of-care testing units.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.